Filing Flows › Zomedica (ZOMDF) › Q3 2026 › vs Q3 2025
Zomedica (ZOMDF) Q3 2026 vs Q3 2025 (year over year)
Zomedica's revenue rose $1.8M (+22%) from $8.1M in Q3 2025 to $9.9M in Q3 2026. The biggest changes: Consumables +$1.4M (+26%); Engineering +$498K (+103%); Capital −$187K (-9%).
Zomedica, Q3 2026: revenue $9.9M (+22% year over year), operating margin -34.6%, net loss $3.2M, operating cash flow −$2.8M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Consumables | $6.8M | $5.4M | $1.4M | +26% |
| Capital | $2.0M | $2.2M | −$187K | -9% |
| Engineering | $981K | $483K | $498K | +103% |
| Other | $116K | $36K | $80K | +222% |
| Revenue | $9.9M | $8.1M | $1.8M | +22% |
| Other income, net | $268K | $466K | −$198K | -42% |
| Net loss | $3.2M | $6.1M | −$3.0M | -48% |
| Costs & expenses | $13.3M | $14.7M | −$1.4M | -9% |
| Operating costs | $13.3M | $14.7M | −$1.4M | -9% |
| Income tax | $9K | −$19K | $28K | — |
| Cost of revenue | $3.9M | $2.7M | $1.2M | +45% |
| Research & development | $1.2M | $1.8M | −$580K | -33% |
| Sales & marketing | $3.6M | $4.4M | −$798K | -18% |
| General & admin | $4.7M | $5.9M | −$1.2M | -20% |
| Operating cash sources | $4.6M | $6.6M | −$2.0M | -30% |
| Depreciation & amortization | $1.8M | $1.9M | −$76K | -4% |
| Cash used in operations | $2.8M | $4.7M | −$1.9M | -41% |
| Net loss absorbed | $3.2M | $6.1M | −$3.0M | -48% |
| Working capital & other | $1.4M | $1.3M | $121K | +9% |
Questions
How much did Zomedica's revenue grow year over year in Q3 2026?
Zomedica's revenue rose $1.8M (+22%) from $8.1M in Q3 2025 to $9.9M in Q3 2026.
What drove Zomedica's revenue change in Q3 2026?
Consumables +$1.4M (+26%); Engineering +$498K (+103%); Capital −$187K (-9%).